A recently FDA-approved ADC, Brentuximab-Vedotin, targets CD30 receptor in Hodgkin's lymphomas [76, 77] which requires lysosomal traffic for its efficacy [5], although the mechanisms of lysosomal trafficking of CD30-bound ADC remain unknown. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.